Clayton Christensen - Amdocs Director
| DOX Stock | USD 86.52 0.05 0.06% |
Director
Dr. Clayton M. Christensen is Director of the Company. He was a director of Amdocs since April 2015. Dr. Christensen is the Kim B. Clark Professor of Business Administration at the Harvard Business School where he was a faculty member since 1992. He also served as President and Chairman of CPS Technologies, an industrial materials company, from 1984 to 1989. From 1979 to 1984, Dr. Christensen worked as a consultant and project manager for the Boston Consulting Group. Dr. Christensen is the founder of Rose Park Advisors, an investment firm, Innosight LLC, an innovation consulting firm, and the Christensen Institute for Disruptive Change, a nonprofit organization focused on innovation. He is a director of Tata Consultancy Services, an IT consulting firm and part of the Tata group, Franklin Covey Co., a public company focused on performance improvement, and Intermountain Healthcare, a notforprofit healthcare provider. since 2015.
| Age | 66 |
| Tenure | 9 years |
| Address | 625 Maryville Centre Drive, Saint Louis, MO, United States, 63141 |
| Phone | 314 212 7000 |
| Web | https://www.amdocs.com |
Amdocs Management Efficiency
The company has Return on Asset of 0.071 % which means that on every $100 spent on assets, it made $0.071 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1562 %, implying that it generated $0.1562 on every 100 dollars invested. Amdocs' management efficiency ratios could be used to measure how well Amdocs manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.10 in 2024. Return On Capital Employed is likely to drop to 0.14 in 2024. At this time, Amdocs' Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 307 M in 2024, whereas Total Assets are likely to drop slightly above 4.5 B in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Sandra Bergeron | F5 Networks | 59 | |
| Howard Schmidt | Qualys Inc | 65 | |
| Jonathan Chadwick | F5 Networks | 51 | |
| Louis Simpson | VeriSign | 81 | |
| Daniel Hesse | Akamai Technologies | 64 | |
| Dan Propper | Check Point Software | 77 | |
| Shai Weiss | Check Point Software | N/A | |
| Monte Ford | Akamai Technologies | 58 | |
| Ping Wai | Global Blue Group | N/A | |
| Michael Dreyer | F5 Networks | 54 | |
| Yoav Chelouche | Check Point Software | 65 | |
| William Chenevich | VeriSign | 70 | |
| Michel Combes | F5 Networks | 56 | |
| Jorge Junquera | Evertec | 72 | |
| David Schaeffer | CyberArk Software | 57 | |
| Tal Shavit | Check Point Software | N/A | |
| Todd Headley | Qualys Inc | 54 | |
| Olga Botero | Evertec | 57 | |
| Aldo Polak | Evertec | 43 | |
| Shikhar Ghosh | Wex Inc | 62 | |
| Eric Duprat | Wex Inc | 55 | |
Management Performance
| Return On Equity | 0.16 | |||
| Return On Asset | 0.071 |
Amdocs Leadership Team
Elected by the shareholders, the Amdocs' board of directors comprises two types of representatives: Amdocs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amdocs. The board's role is to monitor Amdocs' management team and ensure that shareholders' interests are well served. Amdocs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amdocs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joshua Sheffer, CEO President | ||
| Darcy Antonellis, Head Media | ||
| Oren Marmur, Head Network | ||
| Richard LeFave, Independent Director | ||
| Matthew Smith, Corporate Secretary | ||
| John MacDonald, Director | ||
| Idit Aronsohn, Inclusion Responsibility | ||
| Zohar Zisapel, Independent Director | ||
| Simon Olswang, Independent Director | ||
| Anshoo Gaur, Division President of Amdocs Devel. Center India Pvt Ltd | ||
| Elizabeth McDermon, Secretary and VP of Corporate Strategy of Amdocs Inc. | ||
| Giora Yaron, Director | ||
| Gary Miles, Chief Officer | ||
| Shuky Sheffer, Senior Vice President and President of Customer Business Group, Amdocs Management Limited | ||
| Robert Minicucci, Independent Chairman of the Board | ||
| Mustafa Oyumi, Head Strategy | ||
| Clayton Christensen, Director | ||
| James Kahan, Independent Director | ||
| Rajat Raheja, Division President Amdocs Development Center India Pvt. Ltd | ||
| Avishai Sharlin, GM President | ||
| Adrian Gardner, Independent Director | ||
| Tamar RapaportDagim, Senior Vice President and CFO of Amdocs Management Limited | ||
| John McLennan, Independent Director | ||
| Matt Smith, IR Contact Officer | ||
| Julian Brodsky, Independent Director | ||
| Anthony Goonetilleke, Group Strategy | ||
| Eli Gelman, Director, Member of Technology and Innovation Committee, CEO of Amdocs Management Limited and President of Amdocs Management Limited |
Amdocs Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amdocs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | |||
| Return On Asset | 0.071 | |||
| Profit Margin | 0.11 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 10.3 B | |||
| Shares Outstanding | 116.5 M | |||
| Shares Owned By Institutions | 97.33 % | |||
| Number Of Shares Shorted | 1.89 M | |||
| Price To Earning | 19.03 X | |||
| Price To Book | 2.81 X |
Amdocs Investors Sentiment
The influence of Amdocs' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Amdocs. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Amdocs' public news can be used to forecast risks associated with an investment in Amdocs. The trend in average sentiment can be used to explain how an investor holding Amdocs can time the market purely based on public headlines and social activities around Amdocs. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Amdocs' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Amdocs' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Amdocs' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Amdocs.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Amdocs in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Amdocs' short interest history, or implied volatility extrapolated from Amdocs options trading.
Pair Trading with Amdocs
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amdocs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amdocs will appreciate offsetting losses from the drop in the long position's value.Moving against Amdocs Stock
| 0.78 | NN | Nextnav Acquisition Corp Tech Boost | PairCorr |
| 0.69 | EGIO | Edgio Inc Upward Rally | PairCorr |
| 0.6 | GB | Global Blue Group | PairCorr |
| 0.55 | VERI | Veritone Buyout Trend | PairCorr |
The ability to find closely correlated positions to Amdocs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amdocs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amdocs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amdocs to buy it.
The correlation of Amdocs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amdocs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amdocs moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amdocs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amdocs. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Amdocs Stock please use our How to Invest in Amdocs guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Amdocs Stock analysis
When running Amdocs' price analysis, check to measure Amdocs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amdocs is operating at the current time. Most of Amdocs' value examination focuses on studying past and present price action to predict the probability of Amdocs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amdocs' price. Additionally, you may evaluate how the addition of Amdocs to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is Amdocs' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amdocs. If investors know Amdocs will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amdocs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.18 | Dividend Share 1.74 | Earnings Share 4.68 | Revenue Per Share 41.665 | Quarterly Revenue Growth 0.05 |
The market value of Amdocs is measured differently than its book value, which is the value of Amdocs that is recorded on the company's balance sheet. Investors also form their own opinion of Amdocs' value that differs from its market value or its book value, called intrinsic value, which is Amdocs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amdocs' market value can be influenced by many factors that don't directly affect Amdocs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amdocs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amdocs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amdocs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.